Missouri marijuana regulators champion the “effectiveness” track and trace and testing regulations

Missouri marijuana regulators champion the “effectiveness” track and trace and testing regulations


On Monday, the Division of Cannabis Regulation in Missouri issued a new guidance document touting the effectiveness of the state’s track and trace system and testing regulations in efforts to combat criticisms and concerns generated following the massive recall of more than 60,000 product SKUs.

One of the primary questions tackled in the guidance document was the contradiction where marijuana products recorded in Metrc as passing all required testing could still pose potential health risks, an issue raised as none of the final products recalled had ever been reported to cause adverse effects and were tested by licensed Missouri labs.

The letter reads, “If marijuana product is recorded in Metrc as passing all required testing, how can a product still present a potential health risk?

“Intentional falsification of Metrc records or non-compliance with test sample requirements can result in unreliable test results. Testing results in the regulated cannabis industry are only as
good as compliance with sampling requirements and only as good as compliance with tracking requirements. Where records are falsified or sampling requirements are not followed, a passing
test result does not mean all cannabis in a harvest or production lot has been appropriately evaluated.

“Incorporation of unregulated cannabis into regulated product can also present health risks that the required testing regime would not detect. Unregulated cannabis is often grown or processed
with methods or treatments that cannabis in a regulated setting would not be subjected to. For example, chemical conversion of CBD to produce THC can result in product with harmful
residual solvents, other harmful compounds, and even new compounds of unknown impact.
Also, misuse of highly toxic and illegal pesticides in unregulated cannabis production can cause either acute health risks or health risks that accumulate over time and with repeated exposure.
Missouri’s cannabis testing regulations are some of the most stringent in the nation. However, these testing regulations are designed specifically for Missouri’s regulated market where
licensees are highly motivated to create products without use of toxic and illegal compounds and subjected to layers of oversight to ensure they do not engage in such behavior.”

The document continues, “If licensees can falsify tracking information in ways that cause public health risks, how can downstream licensees protect themselves from purchasing noncompliant product from bad actors?


“The risk of bad actors attempting to circumvent regulatory requirements exists in every regulated industry. However, DCR is committed to investigating any evidence of tracking and testing
evasion/manipulation and treating these events as particularly egregious violations. Where such behavior is found, DCR will use all possible avenues to ensure consequences are appropriately severe and public health is protected, as Article XIV requires. Licensees can take measures to develop best practices for reviewing the legitimacy of the product they are acquiring, such as questioning unusually low prices and unusually high availability of supply, or asking for evidence of the source of the product as a matter of course. Licensees may also wish to establish contractual arrangements for return or refund of products later deemed noncompliant.”

Missouri’s cannabis industry saw total sales drop more than 3% in August, bringing in $119 million for the month, the lowest monthly sales total since the first full month of recreational marijuana sales in March.

The guidance from DCR is targeted to combat controversy surrounding the process of the recall and the impact it has had on the industry since.

DCR continues to battle Delta Extractions, the company named as the producer of the distillate used in the recalled products, with the Administrative Hearing Commission set to hear both parties on September 29.

Delta has maintained in hearings that the company acted in accordance with the original language of rules regulating medical marijuana and within standard operating procedures accepted by the Division, and had been in communication with the Division throughout the company’s operation.